Contineum Therapeutics Says Phase 2 Major Depressive Disorder Study Fails to Meet Primary Efficacy Endpoint
MT Newswires Live
3 hours ago
Contineum Therapeutics (CTNM) said late Monday the phase 2 MOONLIGHT-1 trial of JNJ-5120/PIPE-307 for the treatment of major depressive disorder did not meet its primary efficacy endpoint.
JNJ-5120/PIPE-307 is being developed by Johnson & Johnson (JNJ) under a global license and development agreement, the company noted.
The study evaluated improvement from baseline in the Montgomery-Asberg Depression Rating Scale total score at Day 5 compared with placebo, the company said, adding that the treatment was well tolerated and showed no new safety signals.
Johnson & Johnson is continuing to review the trial data, including prespecified exploratory endpoints, to determine next steps for the program, according to a statement.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.